No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration; for GIST, tyrosine kinase inhibitor can be continued for up to 3 days prior to initiation of study treatment
No treatment with immunotherapy =< 21 days before re-registration; no treatment with biologic therapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before re-registration; no treatment with nitrosourea or mitomycin =< 42 days before re-registration
No treatment with biological therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration
No investigational agent within 21 days prior to registration
No investigational therapy within 14 days prior to registration
Patients must not have any anticancer therapy or investigational agent within 28 days prior to step 1 registration
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
Other investigational treatment during or within 30 days before starting study registration
Treatment with any therapeutic investigational agent within 28 days prior to study registration.
Patients must not have received treatment with any chemotherapy, immunotherapy, radiotherapy or an investigational agent for malignancy within the 28 days preceding study registration; patients may not have received treatment with nitrosoureas or mitomycin within the 42 days prior to study registration; patients may not have received treatment with a small molecule targeted agent (including off-label or investigational use) within 14 days preceding study registration, provided this represents at least 7 half-lives for that agent; toxic effects from any prior therapy (except alopecia) must have resolved to grade 1 or less according to National Cancer Institute (NCI) CTCAE version (v)4.0 or to the patientâ€™s baseline by the time of registration
Treatment with any investigational agent or approved therapy within 28 days
Treatment with any investigational agent within 14 days prior to being registered for protocol therapy
No treatment with any investigational agent for any medical condition within 28 days prior to being registered for protocol therapy
Patients who have received any other investigational agent =< 28 days prior to registration are not eligible
No treatment with any investigational agent within 30 days prior to being registered for protocol therapy
No treatment with any investigational agent within 30 days prior to registration for protocol therapy
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration
Treatment with any investigational agent within 30 days prior to registration for protocol therapy
Treatment with any investigational agent within 14 days prior to being registered for protocol therapy
Prior treatment with any other agent that may affect M-protein =< 30 days prior to registration
Use of an investigational agent within the previous 28 days of study registration
Anti-cancer therapy or any treatment with an investigational agent within 30 days prior to randomization
Treatment with any other investigational agent within 28 days prior to registration. Subjects must not be treated with any other investigational agent while on protocol specified therapy.
No treatment with any investigational agent within 30 days prior to registration for protocol therapy.
Investigational agent within 21 days prior to day 1 of protocol therapy
Received an investigational agent within 30 days prior to registration
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
Subjects must have received their last dose of investigational or biologic agent >= 7 days prior to study registration\r\n* In the event that a subject has received an investigational or biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to registration\r\n* If the investigational or biologic agent has a prolonged half-life (>= 7 days) then at least three (3) weeks must have elapsed prior to registration
No treatment with any investigational agent within 30 days prior to study registration.
Treatment with any investigational agent within 14 days prior to being registered for protocol therapy
Treatment with any investigational agent within 28 days prior to registration.
Any investigational agent is acceptable if administered >= 30 days before registration
Received treatment with radiation therapy or investigational therapy =< 28 days prior to registration
No treatment with any investigational agent within 14 days prior to registration for protocol therapy. NOTE: If treated with investigational agent within 14 days prior to registration, AE must be resolved back to baseline.
Systemic therapy or investigational agent administered < 28 days prior to treatment with nintedanib
Treatment with any investigational agent within 30 days prior to registration for protocol therapy
Administration of any investigational agent =< 30 days prior to pre-registration
